|
Developed by 
|
Supported by 
|
AKG-100
Developer(s)
|
Akagera Medicines Originator
https://www.akageramedicines.com/
United States of America Akagera Medicines is a clinical-stage biopharmaceutical company founded in 2018 that develops novel lipid-nanoparticle and liposomal formulations of therapeutics and vaccines to treat infectious diseases such as Lassa Fever, HIV, RSV, and Influenza. |
Drug structure
AKG-100 Structure Placeholder
lapal.ch
Mechanism of Action of AKG-100 Liposomal nanoparticle
https://www.akageramedicines.com/test-page-mel/#jump
Drug information
Associated long-acting platforms
Inorganic nanoparticles
Administration route
Intravenous
Therapeutic area(s)
Use case(s)
Use of drug
Ease of administration
Frequency of administration
User acceptance
Dosage
Available dose and strength
Strength: 85mg/10mL; Dose : up to 850 mg (under Phase 1 Multi ascending dose (MAD) investigation)
Maximum dose
850 mg adult dose
Recommended dosing regimen
Not provided
Additional comments
Not provided
Dosage link(s)
Not provided
Drug information
Drug's link(s)
Not provided
Generic name
Brand name
Compound type
Drug class/category
Lifecycle status
Summary
Approval status
Regulatory authorities
Safety
Efficacy
Evidence Summary
Delivery device(s)
Not provided
Scale-up and manufacturing prospects
Scale-up prospects
Not provided
Tentative equipment list for manufacturing
Not provided
Manufacturing
Not provided
Specific analytical instrument required for characterization of formulation
Not provided
Clinical trials
Not providedExcipients
Proprietary excipients used
Not provided
Novel excipients or existing excipients at a concentration above Inactive Ingredients Database (IID) for the specified route of administration
Not provided
Residual solvents used
Not provided
Patent info
Description
Liposome composition of a oxazolidinone compound (Formula I)
Brief description
Aspects of the disclosure relate to various liposomal compositions of oxazolidinone compounds, and related methods of manufacturing and using the oxazolidinone liposome compositions. In some embodiments, the liposome compositions have improved storage stability with regard to component degradation.
Representative patent
WO2023122759
Category
Composition
Patent holder
AKAGERA MEDICINES, INC.
Exclusivity
Not provided
Expiration date
December 22, 2042
Status
Granted: ZA Pending: AU, AR, BR, CA, CN, EP, HK, KR, IL, IN, JP, NZ, MX, US
Description
Oxazolidinone compounds, liposome compositions comprising oxazolidinone compounds and methods of use thereof
Brief description
Compositions and methods for the treatment of tuberculosis, as well as other mycobacterial and gram positive bacterial infections are disclosed. These compositions contain a highly potent and selective oxazolidinone encapsulated with high efficiency to maximize dosing potential of low toxicity drugs, and are stable in the presence of plasma. The compositions are long circulating and retain their encapsulated drug while in the circulation following intravenous dosing to allow for efficient accumulation at the site of the bacterial or mycobacterial infection. The high doses that can be achieved when combined with the long circulating properties and highly stable retention of the drug allow for a reduced frequency of administration when compared to daily or twice daily administrations of other drugs typically utilized to treat these infections.
Representative patent
WO2021258013
Category
Compound, Formulation, Use
Patent holder
Akagera Medicines Inc
Exclusivity
Not provided
Expiration date
June 18, 2041
Status
Granted: AP (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), AU, CN, EA (AM, AZ, BY, KG, KZ, RU, TJ, TM), JP, KR, MX, US, Pending: BR, CA, EP, IL, IN, NZ, OA (BF, BJ, CG, CI, CM, CF, TD, KM, GQ, GA, GN, GW, ML, MR, NE, SN, TG), SG, ZA
Supporting material
Publications
There are no publication
Additional documents
No documents were uploaded